At least a dozen trucks in New York selling marijuana were towed by the authorities. The police claim that towing the vehicles was unrelated to cannabis.
New York isn’t officially selling legal marijuana, despite the city crawling with cannabis businesses, from trucks to pop-up shops.
This week, the New York City Sheriff’s office seized about a dozen Weed World Candies trucks, which, as we’ve reported previously, do not sell anything that contains THC, “although customers have reported being told otherwise, and in at least one instance, a spokesperson for the company said their products contain CBD.”
Per NBC New York, the trucks had an outstanding parking debt of $504,000, with a ticket debt in judgement of $316,000. Some of the trucks were towed because of parking debt, while others were parked illegally.
“This has absolutely nothing to do with marijuana, it only has to do with unpaid debt. Judgement debt, that’s not paid and owed to the city of New York,” said Maureen Kokeas, NYC Deputy Sheriff. “The Department of Finance has communicated with these parties many, many, many times over many years trying to collect this debt, and the debt was ignored — so we went out and took enforcement action.”
New York’s unregulated cannabis market has facilitated much conversation. While cannabis is legal, the city has yet to establish a functioning cannabis market, confusing many. Earlier this month, NYC Mayor Eric Adams made his stance clear, asking people to have fun, light up and spend money.
“Enjoy yourself, light up, but most importantly, spend some money,” he said at the Cannabis World Congress and Business Expo at Javits Center in Manhattan. When discussing unlicensed cannabis businesses, Adams said that instead of handing out fines he believed in giving them warnings and helping them transition towards a legitimate business.
Cannabis dispensaries in New York have no official start date yet, but experts predict businesses will be up and running by late this year or early 2023.
While further research is needed, these results are a great start as they offer hope to the approximately 250,000 people worldwide struggling with this devastating condition.
MGC Pharmaceuticals , a publicly-traded cannabis company, recently finalized pre-clinical trial research of cannabinoids as a potential treatment for glioblastoma, anaggressive brain cancer. The results were positive, reported CityA.M.
The European-based bio-pharma company specializing in the production and development of phytomedicines said that the three-year in-vitro trial delivered “outstanding results.”
Photo by KATERYNA KON/SCIENCE PHOTO LIBRARY/Getty Images
Study Highlights
The research, conducted in collaboration with the National Institute of Biology in Slovenia with 30 biopsy samples from 18 patients, first examined how cannabinoids such as CBD can be used as a treatment for cancerous tumors. MGC also researched THC and later replaced it with cannabigerol, known as CBG, which has no known psychotropic effects.
The study took more than 5,800 cell tests to determine the most efficient concentration and ratios of CBD and CBG in the treatment formulation.
The results revealed the efficacy of cannabinoids in treating glioblastoma, as well as the most efficient ratio of CBD:CBG in inhibiting the tumor’s viability, causing a cascade of biological processes resulting in the death of glioblastoma and stem cells, reported BusinessCann. This is important because glioblastoma stem cells are the primary cause of the disease’s progression and are resistant to standard treatments. Glioblastoma is the most common, fast-growing, and aggressive brain tumor. Composed of diverse cell types, the prognosis is always poor.
“The results of this trial are enormously exciting both for the company, and for the treatment of fatal cancerous tumors,” said Roby Zomer, co-founder and managing director at MGC Pharmaceuticals.
“MGC Pharma’s research has demonstrated the effect of naturally derived cannabinoid products on stage IV brain tumors without the use of toxic chemotherapy components. We are proud of the work achieved thus far and are looking forward to advancing our proprietary formulation to the next stage of clinical trials.”
Previous Research
This is not the first successful research on the potential of CBD as a treatment for this type of brain tumor.
The study suggested that inhaled CBD reduces the size of glioblastoma through the reduction of the essential support of its microenvironment. Researchers chose the inhaled approach to make sure the compound found in the cannabis plant reached the brain.
“We saw a significant reduction in the size of the tumor and its microenvironment was different,” after only seven days of treatment, said Dr. Babak Baban, immunologist and associate dean for research at the Dental College of Georgia at Augusta University.
In eight days the aggressive brain tumor was formed in the brain of the mice, and the following day they started treating them with CBD via inhalation or placebo. The researchers discovered that CBD altered the tumor’s ecosystem, or supportive tumor microenvironment, and restored levels of inflammation that attack glioblastoma.
“It is about immune balance,” said Baban, the corresponding author of the study.
He explained that the human immune system is regularly fighting cancerous or precancerous cells, but when a tumor is completely established, it takes charge. This means that the tumor creates a state of more chronic inflammation that ends up protecting it from the immune system.
While further research is needed, these results are a great start as they offer hope to the approximately 250,000 people worldwide struggling with this devastating condition.
Does cannabis use, both medical and recreational, have a negative impact on cognitive function? As the number of studies focusing on cannabis exposure and cognitive impairment with different findings grows, the topic is becoming more controversial.
A study conducted in 2001 and published in the journal Archives of General Psychiatry revealed that “the former marihuana smokers did not show any cognitive impairments,” the same as a study published four years later in the journal Neurotoxicology and Teratology.
On the other end of the spectrum are studies suggesting the opposite. As a rule, those kinds of studies mainly focus on the long-term outcomes of those who started using marijuana earlier in life, comparing statistically significant changes in cognitive functioning among those who use cannabis and those who don’t.
New Research
One such example is recent research that followed 1,037 New Zealanders from age 3 to age 45 to determine the effect marijuana has on brain function.
Published in The American Journal of Psychiatry, the study found that those who have been using cannabis long-term and on a regular basis showed cognitive impairment after all.
Besides a 5.5 points decline in users’ IQs from childhood to midlife, the results confirmed some deficits in learning and processing speed compared to those who are not marijuana users.
The Michigan House Committee on Regulatory Reform held a hearing of testimonies on Tuesday about allowing people younger than 21, but at least 18 to work in the cannabis industry in Michigan, reported Fox47News.
Currently, employees at adult-use dispensaries and cultivation facilities must be 21 or older. State Rep. Kevin Coleman (Democratic Party) is trying to change this.
“People have to be 21 to work in cannabis and that doesn’t matter if it’s on the science aspect, cultivation, marketing, sales, so House Bill 6061 is simple, what it does is it would lower the age from 21 to 18,” Rep. Coleman said during his testimony.
One of his arguments for pushing this change is a shortage of cannabis workers.
“We have folks, young people, who are in these college programs or who are trying to start their careers off, who are unable to get involved in the industry because they might be 18, 19, or 20. We want to give young people the opportunity to learn on the job,” Coleman said.
Committee members raised questions about the risk that younger workers could begin consuming cannabis. Micah M. Siegal, who testified on behalf of a Lansing-based marijuana retailer, Pure Options, argued that the risk for that is low.
“Our products are extraordinarily regulated, and the transactions we engage in are always on camera. Because of this regulatory oversight, the risk of diversion of the product to minors is minimal,” Siegal said.
In Maine, marijuana consumers are turning to legal sources over the black market, an achievement for the state and for cannabis proponents.
Marijuana proponents argue that establishing a legal cannabis industry is an effective way of curbing black market marijuana and preventing its risks. While cannabis industries around the country are relatively new, and black market businesses have years of advantage over them, Maine appears to be reaping the benefits of the legal cannabis industry.
According to a new report from the state’s Office of Cannabis Policy (OCP), legal marijuana is impacting black market sales, and the “current illicit market has diminished more than expected.”
The report examined feedback 2,000 Maine residents, with 64% of them claiming that they obtained marijuana products from legal sources. The report found that the majority of young adult users and those who prioritized their cannabis quality turned to legal stores in January of 2021.
Other interesting findings include the fact that people who lived closer to cannabis shops were more likely to seek out legal cannabis products, and that people who purchased legal marijuana had the same risk as others to experience cannabis use disorder and driving while impaired.
Erik Gundersen, director of the OCP, discussed these results in a press statement, claiming that they’re positive for legal cannabis and that they reinforce the benefits of having a functioning legal market. “We are pleased to release this report that highlights the successful launch of Maine’s adult use market,” he said. The findings in this report point to policies and practices that promote and preserve public health and safety, while allowing legal businesses to compete.”
Study authors are calling these results “an achievement in both public health and cannabis policy,” showing that legal cannabis provides revenue for the state and encourages the safe and appropriate use of the drug.
A new nationwide study reveals consumer confusion around U.S. standards for cannabis product safety and quality, showing there is a widely-held, inaccurate assumption that cannabis products have the same basic protections that exist for food, pharmaceuticals and personal care products in the U.S.
The national study was conducted online by The Harris Poll on behalf of SICPA, a leading provider of regulatory compliance solutions, and the Foundation of Cannabis Unified Standards (FOCUS) among over 2,000 U.S. adults. Results include:
Via Anton Petrus/Getty
Nearly three-quarters of Americans overall (72%) and 80% of American cannabis consumers think cannabis products are grown and produced using consistent product safety standards (regardless of which state they are legally purchased in).
More than four in five Americans overall (81%) and 84% of cannabis consumers think that no matter where they are located, the businesses licensed to grow and produce cannabis products must meet consistent environmental standards.
More than three-quarters of Americans overall (77%) and 81% of cannabis consumers, believe cannabis employers are held to the same health and safety standards for their workers as every other industry.
“Our new survey shows Americans are wholly misinformed about the lack of basic safety and quality protections for cannabis products in many states,” stated Karen Gardner, chief marketing officer, SICPA US. “Even cannabis consumers themselves aren’t aware that in states where products are legal, there are no uniform standards, leaving lots of room for unsafe, poor-quality products on the market.”
Also surveyed in the SICPA-Harris Poll were sentiments around support for having the federal government establish standards for cannabis products. An overwhelming 84% of Americans overall and 84% of cannabis consumers support setting federal standards for product safety and quality for cannabis products produced or sold in the U.S. Similarly, 83% of Americans overall and 83% of cannabis consumers support the federal government setting standards for environmental protections that must be met by the U.S. cannabis industry in the U.S.
The poll showed large support among Americans also exists for decriminalization and/or legalization of cannabis products. Nearly three in four (74%) Americans overall and nearly four in five (79%) cannabis consumers are in favor of decriminalization and over three in four Americans (78%) and a large majority (86%) of cannabis consumers support the legalization of cannabis at the national level.
The SICPA-Harris Poll survey also measured cannabis use among Americans, finding 55% of Americans have used cannabis products at some point in time, with more than two in five (42%) stating they’ve used cannabis products in the past 12 months, and 16% saying they consumed cannabis products for the first time in the past 12 months.
This is the third SICPA-The Harris Poll survey on cannabis; in February, the second survey showed overwhelming support among cannabis consumers for more in-depth information about the products they use. The first poll, released last Fall, showed broad support among Americans for securely labeling cannabis products to verify their legitimacy and safety in the marketplace.
The best way to make use of CBD for weight loss is to also approach it holistically, ensuring you are exercising regularly, eating nutritiously, and getting at least 8 hours of sleep a night.
For weight-conscious individuals, it can be confusing to navigate the CBD market. But it’s natural even for people at a healthy weight to be interested in maintaining it to avoid being overweight. After all, being overweight or worse, obese, has been associated with numerous preventable illnesses such as stroke, type 2 diabetes, high blood pressure, osteoarthritis, coronary heart disease, and more. It’s always in your best interest to keep your weight at a healthy level as much as possible.
It’s known that the tetrahydrocannabinol (THC) content in marijuana products has been linked to inducing appetite and weight gain, albeit at healthy levels when taken in moderation or under medical supervision. So much so that it’s even being used for inducing the appetite of cancer and HIV patients, or those that struggle with eating disorders.
But when it comes to CBD, will it help you lose weight, or will it cause weight gain? The truth is, there’s no clear-cut answer, though the results can vary depending on many factors. Here’s some food for thought, based on existing studies:
How CBD Affects Metabolism
A 2016 study conducted by Korean researchers focused on the impact of CBD on preadipocytes, which are immature fat cells. Their findings suggest that CBD work in three ways to promote “fat browning” otherwise white fat tissue (scientifically known as white adipose tissue or WAT), since browned fat is more effective in weight loss as well as obesity treatments.
Additionally, brown fat is more efficient in metabolizing fat molecules and blood sugar to help us maintain our body’s temperature. The presence of more white fat in the body can increase the risk of heart disease and diabetes while brown fat induces weight loss.
The researchers discovered that CBD works to stimulate genes and proteins that are responsible for breaking down fat. It can also increase the mitochondria activity which strengthens the body’s calorie-burning mechanisms. On top of that, CBD consumption has been found to decrease protein expression for those associated with creating new fat cells in the body.
CBD Decreases Obesity Risk Factors
There are other indirect lifestyle factors that contribute to weight gain. Some of the biggest culprits are stress, anxiety, and lack of sleep.
Stress: Constant exposure to stress leads to an increase in the production of cortisol, which is known as the stress hormone. Cortisol may be the reason why you tend to look for fatty and sugary foods under times of stress, and it’s also associated with a rise in insulin levels. Research shows that CBD works to reduce cortisol levels especially among people who take 300 or 600 mg of CBD daily.
By addressing stress, you can stop weight loss in its track. In addition, CBD is also a mood enhancer. When we’re in a better mood, we can be more motivated to exercise. Many studies, including one from 2021, prove CBD’s efficacy in treating mood disorders and anxiety.
CBD Reduces Risk of Type 2 Diabetes
Type 2 diabetes is extremely common, and this condition is associated with obesity and weight gain. A medical review from 2020 revealed that CBD affects many factors that result in insulin resistance which leads to type 2 diabetes and then weight gain.
For individuals who are genetically predisposed to type 2 diabetes, you may take CBD products as a way to keep your metabolic resistance healthy.
How To Choose CBD Products For Weight Loss
Before going any further, remember that CBD products are not a one-size fits-all solution to lose unwanted pounds. It may cause some people to gain weight while others lose, though there are many factors involved including your lifestyle and metabolism among others.
The myriad of studies out there generally show the consensus that CBD is highly unlikely to cause weight gain by itself. But one also has to keep in mind that marijuana products affect everyone differently; CBD may cause your friend to be hungrier than usual while it may cause you to have a suppressed appetite.
Photo by 24K-Production/Getty Images
The best way to make use of CBD for weight loss is to also approach it holistically, ensuring you are exercising regularly, eating nutritiously and in accordance with your specific health needs, and getting at least 8 hours of sleep a night.
Having said that, here are things you should look out for when shopping for CBD products that will assist with weight loss:
Use CBD products that are low in calories, so stay away from sugar-rich gummies that can contribute to weight gain. Low to zero calorie CBD product examples would include unflavored oils, tinctures, and vapes.
Look for a Certificate of Analysis (COA) or third party testing to identify if there are other compounds within the product you are considering purchasing. If CBD products contain a significant amount of THC, you can get high and experience the munchies, causing weight gain over the long run. A COA is essentially proof that the product contains exactly what the manufacturer says and nothing else.
Experiment with dosages and take note of its effects. It’s generally recommended to start with 5 to 10 mg of CBD within a day. Observe how it makes you feel: does it make you feel relaxed, more alert, focused, or sleepy? Adjust your dose as needed. Eventually you will find the best time and dose to take so that you can modify consumption based on what you need it most. For example, 5mg in the morning may give you a little boost to workout, while 15mg at night can give you the well-rested sleep you need before your morning exercise.
The Sixth Panel of the Superior Court of Justice of Brazil authorized three people to grow marijuana for medicinal purposes, reported O Antagonista. “The Superior Court of Justice decided Tuesday, June 14 to grant two safe conducts that advance the regulation of artisanal marijuana cultivation in Brazil.”
The case should serve as a precedent for lower courts and the advance of cannabis legalization in the potentially huge market of 200 million people. The decision contemplates the use of cannabidiol (CBD) for personal use and allows marijuana cultivation only for medicinal purposes, with a prescription. In addition, this gives home growers a legal precedent that can evolve into more comprehensive legislation as in the case of Argentina, where hemp and medicinal cannabis production are already legally produced in the country.
The use of medical marijuana was legalized in Brazil in 2015, but until now patients could only obtain imported medicinal cannabis products with strict authorization from ANVISA (National Sanitary Surveillance Agency). In 2019, Brazil became the third Latin American country to regulate the sale of medical marijuana products after Uruguay and Colombia.
Manufacturers have to import the semi-finished product and can only operate after receiving a special certificate from ANVISA. The importation of whole plants is still prohibited.
CBD products and those containing less than 0.2% THC can be prescribed normally. Products with 0.2% THC or more can only be prescribed for terminal patients or in cases where the patient is not responding to traditional treatments.
“Achieving cannabis regulation through (ANVISA) could imply that Brazil becomes a key player in the Latin American cannabis market, not only because of its geographic and climatic diversity but also because of how significant the market would be for the Brazilian population,” said Silvia Muñoz, former head of Government Affairs for LATAM at the International Cannabis and Cannabinoids Institute in the Czech Republic during an interview a few years ago.
Which Cannabis Companies Are Already In Business In Brazil?
MediPharm Labs Corp. confirmed in September 2021 a partnership with, XLR8 BRAZIL, a distributor based in Rio de Janeiro. This latest move will strengthen the company’s delivery services to the largest medical cannabis market in Latin America.
The two-year agreement would start from the authorization of the product. Pursuant to it, MedPharm Labs chose to provide a wide range of cannabis concentrate formats for the formulated products that XLR8 BRASIL will subsequently distribute.
“In our opinion, Brazil is destined to be a world power in terms of medical cannabis,” said Thiago Callado, CEO of XLRE.
Several months later, in November, the CBD company Panacea Life Sciences, Inc. confirmed that it was forming a partnership with MyPharma2Go to enter the growing cannabis market in Brazil.
Brazil “is the largest country in South America, with a population of more than 200 million people,” noted Nick Cavarra, executive vice president of sales and marketing for Panacea.
In 2022, ANVISA approved the cannabis-based drug, Cannabis Sativa Extract Ease Labs, which joins ten other drugs already approved by ANVISA in this category. Four of them are derived from the whole plant, while the other six contain only CBD.
The American cannabis company Medical Marijuana, inc. launched its first pharmaceutical subsidiary, HM Pharma, in Brazil in May 2022. Medical Marijuana, Inc.’s subsidiary, HempMeds Brasil, was the first company to legally import products into Brazil in 2015 using the country’s compassionate use laws.
“HempMeds Brazil has imported more than 150 thousand prescription products to Brazil through the compassionate model since 2015, and we continue to grow at an average rate of 50% per year. Our market leadership reflects the quality of our products, customer care, and relationships with physicians,” said Matheus Patelli, CEO of HM Pharma.
Cannabis company Avicanna Inc. completed its first commercial export of 20 kg of full-spectrum high-CBD psychoactive cannabis extract to Brazil in 2021, through its majority-owned Colombian subsidiary Santa Marta Golden Hemp S.A.S. Avicanna products were developed in Canada and manufactured in Colombia.
In 2022, the cannabis firm signed an exclusive license and supply agreement with a South American pharmaceutical company to market its proprietary products. According to information obtained exclusively by El Planteo, the pharmaceutical company that signed the agreement with Avicanna is based in Brazil. Avicanna can earn up to CA 1.3 million ($1.03 million) in license fees if certain short-term milestones are reached.
According to New Jersey state law, any cannabis product resembling food can’t be purchased. This strange ruling appears to be influenced by the news regarding cannabis edibles and children, with Jersey lawmakers believing these products could pose a risk for them.
Over the past year, there have been an increased number of reports of children consuming edibles, which often come in alluring, colorful packages, and contain anything from candy to cookies.
Jersey isn’t the first state to try to curb the issue. New York is currently preparing to launch their legal recreational cannabis industry, with laws intended to prevent children from consuming these products. In the state, edible packages will have to avoid cartoons, bright colors, and any types of fonts that may entice children.
Another factor that has influenced the state’s decision is the way in which edibles are made. In order to make legal edibles, commercial kitchens are needed, which require passing the state’s necessary health and safety standards, a system that’s yet to be set up by the New Jersey Cannabis Regulatory Commission (CRC).
Edibles are some of the most popular ways of consuming marijuana, and while they’re a delicious and convenient way to consume weed, they also have a specific set of medical benefits. Edibles are capable of delivering strong therapeutic results, providing plenty of pain relief in ways that inhaled cannabis isn’t normally associated with. Edibles are also a great option for users who don’t want to inhale any smoke or can’t do so because of health concerns.
While the ban on edibles is a curious new turn for legal marijuana, it’s unlikely for Jersey to prohibit them for long. Once the industry finds its footing and customers start getting acquainted with products, lawmakers will likely have to address the issue and make new rules that protect children yet still deliver the products that people want. It will just take more time.
Cannabis is getting all of the attention right now but, like C. ruderalis, there are other plants that have unique benefits to humanity that are being ignored in favor of what is most popular.
There are a ton of varieties of cannabis, some that will never be popular enough to come across and others that are found in every dispensary. Yet, some strains that would never be popular can make their way into daily use. This happens because these strains have a special trait that only become useful when they’re combined with something we use in daily life—think of how much watermelon has changed since the Renaissance.
The same principle applies to cannabis—breeders have been focusing on specific cannabis traits for centuries, selectively breeding higher potency, more attractive smell, more attractive colorations, and even size. These new plants are technically genetically modified organisms (GMOs), but that term tends to carry a loaded connotation (since certain American companies create GMO plants that are resistant to pesticides and herbicides, ultimately lowering nutritional content and the rest of the not-so-great side effects we’re familiar with).
Cannabis that we know and love today is quite different from the cannabis of the ancient world (or even the 70s, just ask your parents)—it’s stronger, tastier, and all around a better quality plant.
Cannabis ruderalis is one of these varieties of cannabis that would have probably been lost to time if not for a special trait. C. ruderalis originated in the Volga River Valley in Russia (most likely) but was first identified in Siberia in 1924. C. ruderalis has also been found throughout North America and central and eastern Europe; it wasn’t ever a strain that people were interested in until the 1980s when seeds of C. ruderalis were sent to the Seed Bank in Amsterdam.
While growers observed C. ruderalis they noted a special characteristic: flowering based upon maturity rather than on light levels. C. ruderalis developed this trait naturally over millions of years of growing in northern regions where light levels throughout the year vary so drastically that plants must grow quickly or lose out on the energy available in those short summer months. C. ruderalis takes advantage of this by having an extremely quick grow cycle, blooming in just a few weeks, so as to spread its pollen and seeds before the cold winter hits again.
One fact that is a bit confusing is how botanists categorize cannabis. Normally, we think there are two main varieties of cannabis: sativa and indica. These two strains dominate the market and are known for their specific kinds of effects and potency, size, and colorations. C. ruderalis technically is a third strain of cannabis, one that has very low THC levels, doesn’t grow very large, and is generally not a potent strain although it has been smoked in the past. It’s not the only other strain of cannabis, either, even if we exclude hybrids, but the other strains are normally used for crafting hemp products since their fibers are quite resilient.
C. ruderalis has that specific trait that does not rely on photoperiods to produce flowers and even though these buds were not really useful in the cannabis sense of the word “use,” the fact that ruderalis contains this trait at all means that it could impart it to other strains. This comes at a cost, though, because when ruderalis is joined with other strains (whether indica, sativa, or a hybrid) it tends to have very unstable genes, so, unfortunately, the only way to get more autoflowers is by buying hybrid seeds from growers.
Once this unique trait was identified, growers spent decades trying to successfully combine C. ruderalis with C. Indica and C. Sativa until they were able to develop strains that were suddenly more resistant to pests as well as not reliant on a photoperiod. Now, growers are able to speed through the growth cycle in just 10 weeks.
C. ruderalis is a low-THC cannabis variety—does this qualify it has “hemp” in the eyes of regulators? Not necessarily, because C. ruderalis actually has slightly higher THC levels than what would qualify it for hem (which should be somewhere between 0.2 – 0.3% THC content, depending on the country).
At this point, C. ruderalis has only one main purpose, which is breeding with other varieties of cannabis. In fact, C. ruderalis is so useful that growers not only breed it with varieties of indica and sativa, but also with hybrids—it’s a difficult thing to do but as indoor growing becomes more widespread and easier to do, the ease of creating hybrids also increases. C. ruderalis has been bred to make all kinds of amazing plants: Mephisto Mondays, Gelato Auto, and Gorilla Glue have all been autoflowered, so expect to see a lot more interesting varieties come out soon.
And while C. ruderalis has had a short history in the Western eye (and in cannabis culture at large), it has been used as a medicinal herb to treat headaches and pains for centuries because it is one strain with a higher CBD content than a lot of other varieties. Currently, C. ruderalis is being used as a potential cancer treatment (obviously not to treat cancer itself but the side effects of cancer drugs), anxiety, and epilepsy. It is a fascinating strain with a long, unique history worth spending time reading about how impactful cannabis can be in medicine.
But let’s not forget that cannabis is just one medicinal plant out of thousands—we are made of the world and the world is made of us, so a lot of what exists in nature can be used to help our lives and our health. Cannabis is getting all of the attention right now but, like C. ruderalis, there are other plants that have unique benefits to humanity that are being ignored in favor of what is most popular.
It’s important that we remember that we live in a diverse world with a lot of really interesting plants that have the ability to change the way we live so be sure not to get too stuck in one way of thought! That’s our final word for the day.
